Takeda Canada Wins Purchase Deal for Adynovate for Hemophilia A

Takeda Canada Wins Purchase Deal for Adynovate for Hemophilia A

312433

Takeda Canada Wins Purchase Deal for Adynovate for Hemophilia A

Canadian Blood Services (CBS) has awarded a three-year tender — an exclusive bulk purchase agreement aiming to minimize medication cost — to Takeda Canada for the purchase of Adynovate, an injectable replacement therapy for the prevention and treatment of bleeding episodes in people with hemophilia A. This is the second consecutive tender that Takeda has won from CBS for Adynovate, and it includes two one-year options. “Being able to continue to provide Canadian hemophilia patients…

You must be logged in to read/download the full post.